Literature DB >> 21149670

Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions.

Alberto Ocaña1, Eitan Amir, Francisco Vera, Elizabeth A Eisenhauer, Ian F Tannock.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21149670     DOI： 10.1200/JCO.2010.32.0275

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  22 in total

Review 1.  Benefit-risk assessment of bevacizumab in the treatment of breast cancer.

Authors:  Rodrigo Dienstmann; Felipe Ades; Kamal S Saini; Otto Metzger-Filho
Journal:  Drug Saf       Date:  2012-01-01       Impact factor: 5.606

2.  Breast cancer: Neoadjuvant bevacizumab treatment-signal or noise?

Authors:  Harold J Burstein
Journal:  Nat Rev Clin Oncol       Date:  2012-03-13       Impact factor: 66.675

Review 3.  Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis.

Authors:  Christopher Lieu; John Heymach; Michael Overman; Hai Tran; Scott Kopetz
Journal:  Clin Cancer Res       Date:  2011-09-27       Impact factor: 12.531

4.  Bevacizumab in ovarian cancer: unanswered questions.

Authors:  Franco Muggia
Journal:  Drugs       Date:  2012-05-07       Impact factor: 9.546

Review 5.  Overall survival as the outcome for randomized clinical trials with effective subsequent therapies.

Authors:  Edward L Korn; Boris Freidlin; Jeffrey S Abrams
Journal:  J Clin Oncol       Date:  2011-05-09       Impact factor: 44.544

6.  Drugs that lack single-agent activity: are they worth pursuing in combination?

Authors:  Bishal Gyawali; Vinay Prasad
Journal:  Nat Rev Clin Oncol       Date:  2017-03-07       Impact factor: 66.675

7.  Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype.

Authors:  Carmine Carbone; Tania Moccia; Cihui Zhu; Genni Paradiso; Alfredo Budillon; Paul J Chiao; James L Abbruzzese; Davide Melisi
Journal:  Clin Cancer Res       Date:  2011-07-07       Impact factor: 12.531

8.  Failing to improve overall survival because post-protocol survival is long: fact, myth, excuse or improper study design?

Authors:  Vinay Prasad; Andrae Vandross
Journal:  J Cancer Res Clin Oncol       Date:  2014-01-29       Impact factor: 4.553

9.  Vascular changes in tumors resistant to a vascular disrupting nanoparticle treatment.

Authors:  Shweta Sharma; Aman P Mann; Tarmo Mölder; Venkata Ramana Kotamraju; Robert Mattrey; Tambet Teesalu; Erkki Ruoslahti
Journal:  J Control Release       Date:  2017-10-13       Impact factor: 9.776

10.  Does the addition of drugs targeting the vascular endothelial growth factor pathway to first-line chemotherapy increase complete response? A meta-analysis of randomized clinical trials.

Authors:  Yan Li; Xin-Yue Liang; Yi-Qi Yue; Lei Sheng; Ji-Kai Liu; Zhan-Yu Wang; Gang Chen
Journal:  Tumour Biol       Date:  2015-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.